This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
58
Site Reference ID/Investigator# 45022
Rousse, Bulgaria
Site Reference ID/Investigator# 45020
Sofia, Bulgaria
Site Reference ID/Investigator# 45026
Greifswald, Germany
Change in CFA from baseline to the end of double blind treatment
Time frame: 7 days after baseline
CNA, stool fat, stool weight, nutritional parameters, clinical symptomatology, SF-36, BMI
Time frame: 7 days after baseline, and end of open-label period (1 year of open label treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site Reference ID/Investigator# 45025
Hamburg, Germany
Site Reference ID/Investigator# 45027
Heidelberg, Germany
Site Reference ID/Investigator# 45024
Munich, Germany
Site Reference ID/Investigator# 45126
Békéscsaba, Hungary
Site Reference ID/Investigator# 45121
Budaörs, Hungary
Site Reference ID/Investigator# 45127
Dunaújváros, Hungary
Site Reference ID/Investigator# 45115
Gyula, Hungary
...and 5 more locations